JP2023523628A5 - - Google Patents
Info
- Publication number
- JP2023523628A5 JP2023523628A5 JP2022565860A JP2022565860A JP2023523628A5 JP 2023523628 A5 JP2023523628 A5 JP 2023523628A5 JP 2022565860 A JP2022565860 A JP 2022565860A JP 2022565860 A JP2022565860 A JP 2022565860A JP 2023523628 A5 JP2023523628 A5 JP 2023523628A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026037950A JP2026116918A (ja) | 2020-05-01 | 2026-03-10 | Ｉｌｔ結合剤及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019068P | 2020-05-01 | 2020-05-01 | |
| US63/019,068 | 2020-05-01 | ||
| US202063122848P | 2020-12-08 | 2020-12-08 | |
| US63/122,848 | 2020-12-08 | ||
| PCT/US2021/029866 WO2021222544A1 (en) | 2020-05-01 | 2021-04-29 | Ilt-binding agents and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037950A Division JP2026116918A (ja) | 2020-05-01 | 2026-03-10 | Ｉｌｔ結合剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523628A JP2023523628A (ja) | 2023-06-06 |
| JP2023523628A5 true JP2023523628A5 (enExample) | 2024-05-10 |
| JP7834028B2 JP7834028B2 (ja) | 2026-03-23 |
Family
ID=76012027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565860A Active JP7834028B2 (ja) | 2020-05-01 | 2021-04-29 | Ｉｌｔ結合剤及びその使用方法 |
| JP2026037950A Pending JP2026116918A (ja) | 2020-05-01 | 2026-03-10 | Ｉｌｔ結合剤及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037950A Pending JP2026116918A (ja) | 2020-05-01 | 2026-03-10 | Ｉｌｔ結合剤及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11802155B2 (enExample) |
| EP (2) | EP4143229B1 (enExample) |
| JP (2) | JP7834028B2 (enExample) |
| KR (1) | KR20230005978A (enExample) |
| CN (2) | CN116589581A (enExample) |
| AU (2) | AU2021265801B2 (enExample) |
| BR (1) | BR112022021684A2 (enExample) |
| CA (1) | CA3181197A1 (enExample) |
| CL (1) | CL2022003004A1 (enExample) |
| CO (1) | CO2022015208A2 (enExample) |
| ES (1) | ES3039441T3 (enExample) |
| IL (1) | IL297748A (enExample) |
| MX (1) | MX2022013466A (enExample) |
| MY (1) | MY209480A (enExample) |
| PE (1) | PE20221894A1 (enExample) |
| TW (1) | TW202206463A (enExample) |
| WO (1) | WO2021222544A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3740224A4 (en) * | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
| MX2022001841A (es) | 2019-08-12 | 2022-08-17 | Biond Biologics Ltd | Anticuerpos contra ilt2 y uso de los mismos. |
| JP2023537396A (ja) | 2020-08-12 | 2023-08-31 | ビオンド バイオロジクス リミテッド | Ｉｌｔ２に対する抗体およびその使用 |
| EP4232087A4 (en) * | 2020-10-21 | 2024-10-09 | Immune-ONC Therapeutics, Inc. | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS |
| WO2023077521A1 (en) * | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
| CN119156229A (zh) * | 2022-03-04 | 2024-12-17 | D2M生物治疗有限公司 | 抗lilrb1/2抗体及其用途 |
| AU2023231622A1 (en) * | 2022-03-07 | 2024-09-26 | Agenus Inc. | Anti-ilt2 antibodies and uses thereof |
| WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
| WO2023235703A1 (en) * | 2022-05-31 | 2023-12-07 | Ngm Biopharmaceuticals, Inc. | Therapeutic methods using ilt-binding agents |
| TW202409088A (zh) * | 2022-07-08 | 2024-03-01 | 中國商科望（蘇州）生物醫藥科技有限公司 | 抗lilrb2抗體及其用途 |
| EP4628508A1 (en) * | 2022-12-09 | 2025-10-08 | Biodlink Biopharm Co., Ltd. | Anti-ilt4 antibody as well as preparation method therefor and use thereof |
| EP4491230A1 (en) * | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| EP4637924A2 (en) * | 2022-12-23 | 2025-10-29 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| WO2024218650A1 (en) * | 2023-04-19 | 2024-10-24 | Pfizer Inc. | Lilrb1 and lilrb2 antibodies and methods of use thereof |
| WO2025059304A2 (en) * | 2023-09-12 | 2025-03-20 | Agenus Inc. | Methods of treating cancer using ilt2 antibodies and combination therapies |
| GB202314087D0 (en) * | 2023-09-14 | 2023-11-01 | Macomics Ltd | Biomarker for cancer |
| WO2025168070A1 (zh) * | 2024-02-08 | 2025-08-14 | 东曜药业有限公司 | 一种抗ilt2/4单抗的制剂、包含其的药盒及其应用 |
| WO2025191142A2 (en) | 2024-03-15 | 2025-09-18 | Les Laboratoires Servier | Antibodies to lilrb1 and lilrb2 and compositions thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0948623B1 (en) | 1996-12-06 | 2010-01-27 | Schering Corporation | Isolated mammalian monocyte cell genes; related reagents |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| WO2003000199A2 (en) | 2001-06-25 | 2003-01-03 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
| US20040241167A1 (en) | 2001-06-25 | 2004-12-02 | Nicole Suciu-Foca | Ilt3 and ilt4-related compositons and methods |
| AU2002360376B2 (en) | 2001-11-14 | 2006-05-18 | Immunex Corporation | Modulation of LIR function to treat rheumatoid arthritis |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| EP1981522B1 (en) | 2006-01-23 | 2012-09-12 | President and Fellows of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| KR20090082480A (ko) | 2006-11-14 | 2009-07-30 | 제넨테크, 인크. | 뉴런 재생의 조절인자 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| KR20100109923A (ko) | 2007-12-11 | 2010-10-11 | 제넨테크, 인크. | 뉴런 재생의 조정인자 |
| AU2009246443A1 (en) | 2008-05-13 | 2009-11-19 | Genentech, Inc. | Anti-PirB antibodies |
| US20090285803A1 (en) | 2008-05-13 | 2009-11-19 | Jasvinder Atwal | ANTI-PirB ANTIBODIES |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| EP2970373A1 (en) | 2013-03-12 | 2016-01-20 | The Board of Trustees of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
| WO2015179633A1 (en) | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| US20170274003A1 (en) | 2014-09-16 | 2017-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| EP3256163A4 (en) | 2015-02-11 | 2018-10-10 | University Health Network | Methods and compositions for modulating lilr proteins |
| CA3218106A1 (en) | 2015-03-06 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
| CA3019635A1 (en) | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| EP3344263A4 (en) | 2016-08-04 | 2020-07-01 | Memorial Sloan-Kettering Cancer Center | CANCER ANTIGEN TARGETS AND USES THEREOF |
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| JP7194481B2 (ja) | 2017-11-17 | 2022-12-22 | メルク・シャープ・アンド・ドーム・エルエルシー | 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用 |
| JPWO2019107387A1 (ja) | 2017-11-28 | 2020-12-17 | 国立大学法人大阪大学 | マラリア治療薬、マラリアの治療方法、マラリア治療用候補物質のスクリーニング方法、マラリア重症化マーカー、マラリアの重症化の危険度を試験する方法および試験試薬 |
| EP4219559A3 (en) | 2017-12-22 | 2023-10-18 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| EP3740224A4 (en) | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
| MY201995A (en) | 2018-07-09 | 2024-03-28 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
| WO2020023268A1 (en) * | 2018-07-24 | 2020-01-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| NZ789331A (en) | 2019-12-19 | 2026-02-27 | Ngm Biopharmaceuticals Inc | Ilt3-binding agents and methods of use thereof |
| WO2021133036A1 (ko) | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항-lilrb1 항체 및 그의 용도 |
-
2021
- 2021-04-29 CA CA3181197A patent/CA3181197A1/en active Pending
- 2021-04-29 US US17/244,169 patent/US11802155B2/en active Active
- 2021-04-29 BR BR112022021684A patent/BR112022021684A2/pt unknown
- 2021-04-29 AU AU2021265801A patent/AU2021265801B2/en active Active
- 2021-04-29 EP EP21726775.6A patent/EP4143229B1/en active Active
- 2021-04-29 MY MYPI2022005825A patent/MY209480A/en unknown
- 2021-04-29 KR KR1020227042267A patent/KR20230005978A/ko active Pending
- 2021-04-29 MX MX2022013466A patent/MX2022013466A/es unknown
- 2021-04-29 JP JP2022565860A patent/JP7834028B2/ja active Active
- 2021-04-29 IL IL297748A patent/IL297748A/en unknown
- 2021-04-29 CN CN202310455554.XA patent/CN116589581A/zh active Pending
- 2021-04-29 PE PE2022002422A patent/PE20221894A1/es unknown
- 2021-04-29 WO PCT/US2021/029866 patent/WO2021222544A1/en not_active Ceased
- 2021-04-29 EP EP25191395.0A patent/EP4691561A2/en active Pending
- 2021-04-29 CN CN202180045295.2A patent/CN115768524A/zh active Pending
- 2021-04-29 ES ES21726775T patent/ES3039441T3/es active Active
- 2021-04-30 TW TW110115745A patent/TW202206463A/zh unknown
-
2022
- 2022-10-26 CO CONC2022/0015208A patent/CO2022015208A2/es unknown
- 2022-10-27 CL CL2022003004A patent/CL2022003004A1/es unknown
-
2023
- 2023-09-13 US US18/466,722 patent/US12410251B2/en active Active
-
2025
- 2025-08-06 US US19/292,620 patent/US20260226164A1/en active Pending
-
2026
- 2026-03-10 JP JP2026037950A patent/JP2026116918A/ja active Pending
- 2026-06-25 AU AU2026204926A patent/AU2026204926A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL297748A (en) | ilt binding agents and methods of using them | |
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| US20220135675A1 (en) | Anti-tim-3 antibodies and use thereof | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| KR102925710B1 (ko) | 림프구에서의 저해 경로의 중화 | |
| IL302278A (en) | Combination treatment | |
| JP2023532857A5 (enExample) | ||
| RS62038B1 (sr) | Ciljana tgf beta inhibicija | |
| JP2022528030A5 (enExample) | ||
| Saini et al. | Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment | |
| KR102452246B1 (ko) | 암 치료법을 위한 면역 체크포인트 조절을 갖는 단일특이성 및 이중특이성 단백질 | |
| JP2021520201A5 (enExample) | ||
| JP2021520201A (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| CN114790241B (zh) | 抗tigit抗体及其应用 | |
| JP2022553851A5 (enExample) | ||
| AU2020308463A1 (en) | Antibodies for T-cell activation | |
| CN112351794A (zh) | 用于尿路上皮癌的免疫治疗方法 | |
| JP7676594B2 (ja) | 抗ｃｄ９８抗体及びその応用 | |
| Miao et al. | Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells | |
| WO2024173376A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies | |
| AU2019306113A1 (en) | Anti-human PD-L1 antibodies and their uses | |
| AU2023250952A1 (en) | Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 | |
| JP2025515473A (ja) | 改変された細胞傷害性ｔ細胞およびその使用方法 | |
| RU2793167C2 (ru) | Моноспецифические и биспецифические белки с регулированием иммунной контрольной точки для лечения рака |